Decheng Capital LLC Sells 33,700 Shares of Krystal Biotech, Inc. $KRYS

Decheng Capital LLC decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 51.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 32,300 shares of the company’s stock after selling 33,700 shares during the quarter. Krystal Biotech makes up approximately 1.0% of Decheng Capital LLC’s investment portfolio, making the stock its 14th biggest position. Decheng Capital LLC’s holdings in Krystal Biotech were worth $5,702,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Bessemer Group Inc. increased its stake in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares during the period. AdvisorNet Financial Inc acquired a new position in shares of Krystal Biotech during the third quarter valued at $30,000. Salomon & Ludwin LLC acquired a new position in shares of Krystal Biotech during the third quarter valued at $33,000. Caldwell Trust Co bought a new position in Krystal Biotech in the second quarter valued at about $34,000. Finally, MAI Capital Management boosted its holdings in Krystal Biotech by 79.7% in the third quarter. MAI Capital Management now owns 284 shares of the company’s stock valued at $50,000 after acquiring an additional 126 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Down 1.6%

NASDAQ:KRYS opened at $247.26 on Monday. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $298.30. The business’s 50-day moving average price is $270.50 and its two-hundred day moving average price is $223.09. The firm has a market capitalization of $7.23 billion, a price-to-earnings ratio of 36.10 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Activity

In related news, Director Dino A. Rossi sold 18,950 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the transaction, the director owned 78,691 shares of the company’s stock, valued at $20,570,614.31. This trade represents a 19.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kathryn Romano sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 129,164 shares of company stock worth $34,538,578 over the last quarter. 13.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on KRYS. Citigroup boosted their price objective on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Jefferies Financial Group raised their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 18th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $326.25.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.